{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone+capsules&page=2", "query": { "intervention": "Prednisone capsules", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone+capsules&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T11:01:25.014Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02921789", "title": "Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation", "Primary Focal Segmental Glomerulosclerosis (FSGS)" ], "interventions": [ { "name": "Bleselumab", "type": "DRUG" }, { "name": "Basiliximab", "type": "DRUG" }, { "name": "Mycophenolate Mofetil (MMF)", "type": "DRUG" }, { "name": "Tacrolimus Capsules", "type": "DRUG" }, { "name": "Methylprednisone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2017-05-22", "completion_date": "2021-05-18", "has_results": true, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-09-28T11:01:25.014Z", "location_count": 20, "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02921789" }, { "nct_id": "NCT02994927", "title": "A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ANCA-Associated Vasculitis" ], "interventions": [ { "name": "Avacopan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Azathioprine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 331, "start_date": "2017-03-15", "completion_date": "2019-11-01", "has_results": true, "last_update_posted_date": "2025-03-24", "last_synced_at": "2026-09-28T11:01:25.014Z", "location_count": 41, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02994927" }, { "nct_id": "NCT03532022", "title": "Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Congenital Adrenal Hyperplasia" ], "interventions": [ { "name": "Chronocort®", "type": "DRUG" }, { "name": "Standard Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurocrine UK Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 0, "start_date": "2018-10-04", "completion_date": "2021-07-09", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-28T11:01:25.014Z", "location_count": 1, "location_summary": "Morehead City, North Carolina", "locations": [ { "city": "Morehead City", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03532022" }, { "nct_id": "NCT06554639", "title": "A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "MK-5684", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Fludrocortisone acetate", "type": "DRUG" }, { "name": "Diltiazem hydrocholoride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 12, "start_date": "2024-07-11", "completion_date": "2024-08-29", "has_results": false, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-09-28T11:01:25.014Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06554639" }, { "nct_id": "NCT00035555", "title": "Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Rejection", "Kidney Transplantation", "Renal Transplantation" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2001-03", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2014-01-13", "last_synced_at": "2026-09-28T11:01:25.014Z", "location_count": 12, "location_summary": "San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00035555" }, { "nct_id": "NCT00668434", "title": "Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sciatica" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 269, "start_date": "2008-11", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2015-04-28", "last_synced_at": "2026-09-28T11:01:25.014Z", "location_count": 3, "location_summary": "Redwood City, California • Roseville, California • San Jose, California", "locations": [ { "city": "Redwood City", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00668434" }, { "nct_id": "NCT04691804", "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "Fuzuloparib , Abiraterone acetate and Prednisone", "type": "DRUG" }, { "name": "Fuzuloparib Placebo， Abiraterone acetate and Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jiangsu HengRui Medicine Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 496, "start_date": "2021-03-18", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2024-12-31", "last_synced_at": "2026-09-28T11:01:25.014Z", "location_count": 17, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04691804" }, { "nct_id": "NCT07412470", "title": "A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Kidney Transplant Rejection" ], "interventions": [ { "name": "Frexalimab", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "rabbit anti-thymocyte globulin", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "mycophenolate sodium", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 526, "start_date": "2026-03-13", "completion_date": "2033-08-15", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-28T11:01:25.014Z", "location_count": 11, "location_summary": "Atlanta, Georgia • Hines, Illinois • Kansas City, Kansas + 7 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Hines", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07412470" }, { "nct_id": "NCT01241006", "title": "Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma", "Reactive Airway Disease" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alameda County Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 376, "start_date": "2011-01", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2016-01-07", "last_synced_at": "2026-09-28T11:01:25.014Z", "location_count": 1, "location_summary": "Oakland, California", "locations": [ { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01241006" }, { "nct_id": "NCT00774852", "title": "Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis", "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "abatacept", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "azathioprine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "abatacept placebo", "type": "DRUG" }, { "name": "azathioprine placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 137, "start_date": "2008-11", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-09-28T11:01:25.014Z", "location_count": 21, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00774852" } ] }